ADMA BIOLOGICS INC (ADMA)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for ADMA
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ADMA | Chairman of the Compensation Committee and the Audit Committee | 54 | ["Chief Executive Officer at Alchemab Therapeutics","Senior executive at Momenta Pharmaceuticals","Chief Financial and Business Officer at Momenta","Business development professional at Biogen","Experience in venture capital at Advanced Technology Ventures","B.S. in Biology from MIT","Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University"] | ["Compensation Committee","Audit Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Dr. Kwon has been a director of ADMA since October 2021 and currently serves as the Chairman of the Compensation Committee and the Audit Committee. From April 2022 to September 2024, Dr. Kwon served as Chief Executive Officer at Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology. Dr. Kwon held a variety of leadership roles as a senior executive at Momenta Pharmaceuticals from January 2011 until January 2021. Dr. Kwon was previously Chief Financial and Business Officer at Momenta, where he had responsibility for business development, strategy, finance, investor relations, and commercial. Dr. Kwon led public equity financings raising nearly $500 million and led the company s sale to Johnson & Johnson for $6.5 billion. Prior to Momenta, Dr. Kwon was a business development professional at Biogen, driving a variety of transactions. Dr. Kwon previously worked at the venture capital firm Advanced Technology Ventures, investing in early-stage biotech and medical device companies. Dr. Kwon received a B.S. in Biology from the Massachusetts Institute of Technology and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University. Dr. Kwon s extensive strategic and financial experience in the healthcare sector qualifies him to serve as a director of the Company.